Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infect...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-02, Vol.17 (2), p.e0261980 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | e0261980 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Rojas-Serrano, Jorge Portillo-Vásquez, Angelica Margarita Thirion-Romero, Ireri Vázquez-Pérez, Joel Mejía-Nepomuceno, Fidencio Ramírez-Venegas, Alejandra Pérez-Kawabe, Karla Midori Pérez-Padilla, Rogelio |
| description | Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2.
Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection.
127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size. |
| doi_str_mv | 10.1371/journal.pone.0261980 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2627114547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A692691941</galeid><doaj_id>oai_doaj_org_article_9cae99bbd93a4760b5654c732f4305f9</doaj_id><sourcerecordid>A692691941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-b86354b3d2d9dc9fd3e2fbf5859a52445e6704f84d7ac1505ac81e834b72858c3</originalsourceid><addsrcrecordid>eNqNk1uLEzEUxwdR3HX1G4gOCKIPrbnOJD4IpV62sFDwsm8SMrm0WdNJTaba-ulNt7NLR_ZB8pCQ_M4_Of-cUxRPIRhDXMM3V2ETW-nH69CaMUAV5AzcK04hx2hUIYDvH61PikcpXQFAMauqh8UJphBzwOvT4vv5Tsew3amlDzH83LjWlDbEch3DernzcutSGWw5nV_O3o8gL11bLo303bL8HeIPE9PbclJG2eqwcn-MLpV3rVPSl1100j8uHljpk3nSz2fFt48fvk7PRxfzT7Pp5GKkKo66UcMqTEmDNdJcK241Nsg2ljLKJUWEUFPVgFhGdC0VpIBKxaBhmDQ1YpQpfFY8P-iufUiidyYJVKEaQkJJnYnZgdBBXol1dCsZdyJIJ643QlwIGTunvBFcScN502iOJakr0NCKElVjZAkG1PKs9a6_bdOsjFam7aL0A9HhSeuWYhF-CcZQnbPJAq96gb3lJnVi5ZIy3svWhM3h3YQBcv3uF_-gd2fXUwuZE3CtDfletRcVk-xwxSEnMFPjO6g8tFk5lcvIurw_CHg9CMhMZ7bdQm5SErMvn_-fnV8O2ZdH7KGeUvCbzoU2DUFyAFUMKUVjb02GQOy74MYNse8C0XdBDnt2_EG3QTdlj_8C9jcBTQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627114547</pqid></control><display><type>article</type><title>Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Rojas-Serrano, Jorge ; Portillo-Vásquez, Angelica Margarita ; Thirion-Romero, Ireri ; Vázquez-Pérez, Joel ; Mejía-Nepomuceno, Fidencio ; Ramírez-Venegas, Alejandra ; Pérez-Kawabe, Karla Midori ; Pérez-Padilla, Rogelio</creator><contributor>Triche, Elizabeth W</contributor><creatorcontrib>Rojas-Serrano, Jorge ; Portillo-Vásquez, Angelica Margarita ; Thirion-Romero, Ireri ; Vázquez-Pérez, Joel ; Mejía-Nepomuceno, Fidencio ; Ramírez-Venegas, Alejandra ; Pérez-Kawabe, Karla Midori ; Pérez-Padilla, Rogelio ; Triche, Elizabeth W</creatorcontrib><description>Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2.
Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection.
127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0261980</identifier><identifier>PMID: 35139097</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Antibodies ; Antigens ; Antimalarials - therapeutic use ; Antiviral Agents - therapeutic use ; Biology and Life Sciences ; Blood ; Chronic obstructive pulmonary disease ; Clinical trials ; Complications and side effects ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - prevention & control ; Design ; Disease prevention ; Double-Blind Method ; Drug dosages ; Female ; Health aspects ; Health care ; Health Personnel ; Health risks ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - therapeutic use ; Immunoassay ; Infections ; Laboratories ; Malaria ; Male ; Medical personnel ; Medical research ; Medicine and Health Sciences ; Pandemics ; Patient outcomes ; Patients ; People and Places ; Personal protective equipment ; Placebo Effect ; Placebos ; Polymerase chain reaction ; Pregnancy ; Prophylaxis ; Rank tests ; Research and Analysis Methods ; Respiratory diseases ; SARS-CoV-2 - drug effects ; SARS-CoV-2 - isolation & purification ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Tobacco ; Treatment Outcome ; Viral diseases</subject><ispartof>PloS one, 2022-02, Vol.17 (2), p.e0261980</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Rojas-Serrano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Rojas-Serrano et al 2022 Rojas-Serrano et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-b86354b3d2d9dc9fd3e2fbf5859a52445e6704f84d7ac1505ac81e834b72858c3</citedby><cites>FETCH-LOGICAL-c692t-b86354b3d2d9dc9fd3e2fbf5859a52445e6704f84d7ac1505ac81e834b72858c3</cites><orcidid>0000-0002-5032-4076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827445/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827445/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53770,53772,79347,79348</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35139097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Triche, Elizabeth W</contributor><creatorcontrib>Rojas-Serrano, Jorge</creatorcontrib><creatorcontrib>Portillo-Vásquez, Angelica Margarita</creatorcontrib><creatorcontrib>Thirion-Romero, Ireri</creatorcontrib><creatorcontrib>Vázquez-Pérez, Joel</creatorcontrib><creatorcontrib>Mejía-Nepomuceno, Fidencio</creatorcontrib><creatorcontrib>Ramírez-Venegas, Alejandra</creatorcontrib><creatorcontrib>Pérez-Kawabe, Karla Midori</creatorcontrib><creatorcontrib>Pérez-Padilla, Rogelio</creatorcontrib><title>Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2.
Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection.
127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.</description><subject>Adult</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Antimalarials - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>Blood</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - prevention & control</subject><subject>Design</subject><subject>Disease prevention</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health care</subject><subject>Health Personnel</subject><subject>Health risks</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Immunoassay</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Malaria</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Pandemics</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>People and Places</subject><subject>Personal protective equipment</subject><subject>Placebo Effect</subject><subject>Placebos</subject><subject>Polymerase chain reaction</subject><subject>Pregnancy</subject><subject>Prophylaxis</subject><subject>Rank tests</subject><subject>Research and Analysis Methods</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - drug effects</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Tobacco</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uLEzEUxwdR3HX1G4gOCKIPrbnOJD4IpV62sFDwsm8SMrm0WdNJTaba-ulNt7NLR_ZB8pCQ_M4_Of-cUxRPIRhDXMM3V2ETW-nH69CaMUAV5AzcK04hx2hUIYDvH61PikcpXQFAMauqh8UJphBzwOvT4vv5Tsew3amlDzH83LjWlDbEch3DernzcutSGWw5nV_O3o8gL11bLo303bL8HeIPE9PbclJG2eqwcn-MLpV3rVPSl1100j8uHljpk3nSz2fFt48fvk7PRxfzT7Pp5GKkKo66UcMqTEmDNdJcK241Nsg2ljLKJUWEUFPVgFhGdC0VpIBKxaBhmDQ1YpQpfFY8P-iufUiidyYJVKEaQkJJnYnZgdBBXol1dCsZdyJIJ643QlwIGTunvBFcScN502iOJakr0NCKElVjZAkG1PKs9a6_bdOsjFam7aL0A9HhSeuWYhF-CcZQnbPJAq96gb3lJnVi5ZIy3svWhM3h3YQBcv3uF_-gd2fXUwuZE3CtDfletRcVk-xwxSEnMFPjO6g8tFk5lcvIurw_CHg9CMhMZ7bdQm5SErMvn_-fnV8O2ZdH7KGeUvCbzoU2DUFyAFUMKUVjb02GQOy74MYNse8C0XdBDnt2_EG3QTdlj_8C9jcBTQ</recordid><startdate>20220209</startdate><enddate>20220209</enddate><creator>Rojas-Serrano, Jorge</creator><creator>Portillo-Vásquez, Angelica Margarita</creator><creator>Thirion-Romero, Ireri</creator><creator>Vázquez-Pérez, Joel</creator><creator>Mejía-Nepomuceno, Fidencio</creator><creator>Ramírez-Venegas, Alejandra</creator><creator>Pérez-Kawabe, Karla Midori</creator><creator>Pérez-Padilla, Rogelio</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5032-4076</orcidid></search><sort><creationdate>20220209</creationdate><title>Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial</title><author>Rojas-Serrano, Jorge ; Portillo-Vásquez, Angelica Margarita ; Thirion-Romero, Ireri ; Vázquez-Pérez, Joel ; Mejía-Nepomuceno, Fidencio ; Ramírez-Venegas, Alejandra ; Pérez-Kawabe, Karla Midori ; Pérez-Padilla, Rogelio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-b86354b3d2d9dc9fd3e2fbf5859a52445e6704f84d7ac1505ac81e834b72858c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Antimalarials - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>Blood</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - prevention & control</topic><topic>Design</topic><topic>Disease prevention</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health care</topic><topic>Health Personnel</topic><topic>Health risks</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Immunoassay</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Malaria</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Pandemics</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>People and Places</topic><topic>Personal protective equipment</topic><topic>Placebo Effect</topic><topic>Placebos</topic><topic>Polymerase chain reaction</topic><topic>Pregnancy</topic><topic>Prophylaxis</topic><topic>Rank tests</topic><topic>Research and Analysis Methods</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - drug effects</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Tobacco</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rojas-Serrano, Jorge</creatorcontrib><creatorcontrib>Portillo-Vásquez, Angelica Margarita</creatorcontrib><creatorcontrib>Thirion-Romero, Ireri</creatorcontrib><creatorcontrib>Vázquez-Pérez, Joel</creatorcontrib><creatorcontrib>Mejía-Nepomuceno, Fidencio</creatorcontrib><creatorcontrib>Ramírez-Venegas, Alejandra</creatorcontrib><creatorcontrib>Pérez-Kawabe, Karla Midori</creatorcontrib><creatorcontrib>Pérez-Padilla, Rogelio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rojas-Serrano, Jorge</au><au>Portillo-Vásquez, Angelica Margarita</au><au>Thirion-Romero, Ireri</au><au>Vázquez-Pérez, Joel</au><au>Mejía-Nepomuceno, Fidencio</au><au>Ramírez-Venegas, Alejandra</au><au>Pérez-Kawabe, Karla Midori</au><au>Pérez-Padilla, Rogelio</au><au>Triche, Elizabeth W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-02-09</date><risdate>2022</risdate><volume>17</volume><issue>2</issue><spage>e0261980</spage><pages>e0261980-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2.
Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection.
127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35139097</pmid><doi>10.1371/journal.pone.0261980</doi><tpages>e0261980</tpages><orcidid>https://orcid.org/0000-0002-5032-4076</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-02, Vol.17 (2), p.e0261980 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2627114547 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adult Antibodies Antigens Antimalarials - therapeutic use Antiviral Agents - therapeutic use Biology and Life Sciences Blood Chronic obstructive pulmonary disease Clinical trials Complications and side effects Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - prevention & control Design Disease prevention Double-Blind Method Drug dosages Female Health aspects Health care Health Personnel Health risks Humans Hydroxychloroquine Hydroxychloroquine - therapeutic use Immunoassay Infections Laboratories Malaria Male Medical personnel Medical research Medicine and Health Sciences Pandemics Patient outcomes Patients People and Places Personal protective equipment Placebo Effect Placebos Polymerase chain reaction Pregnancy Prophylaxis Rank tests Research and Analysis Methods Respiratory diseases SARS-CoV-2 - drug effects SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Statistical analysis Tobacco Treatment Outcome Viral diseases |
| title | Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T12%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxychloroquine%20for%20prophylaxis%20of%20COVID-19%20in%20health%20workers:%20A%20randomized%20clinical%20trial&rft.jtitle=PloS%20one&rft.au=Rojas-Serrano,%20Jorge&rft.date=2022-02-09&rft.volume=17&rft.issue=2&rft.spage=e0261980&rft.pages=e0261980-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0261980&rft_dat=%3Cgale_plos_%3EA692691941%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627114547&rft_id=info:pmid/35139097&rft_galeid=A692691941&rft_doaj_id=oai_doaj_org_article_9cae99bbd93a4760b5654c732f4305f9&rfr_iscdi=true |